A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 15 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Icotrokinra (Primary)
Indications Plaque psoriasis
Focus Registrational; Therapeutic Use
Acronyms ICONIC-TOTAL
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

07 Nov 2024 According to Protagonist Therapeutics media release, top line results for JNJ-2113 Phase 3 ICONIC-LEAD, in patients with moderate to severe psoriasis expected in Q4 2024.
11 Oct 2024 Planned End Date changed from 17 Feb 2027 to 10 Jun 2027.
23 Apr 2024 Planned End Date changed from 31 May 2027 to 17 Feb 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight